Pacira BioSciences, Inc. (NASDAQ:PCRX) Director Marcelo Bigal Sells 4,912 Shares

Pacira BioSciences, Inc. (NASDAQ:PCRX) Director Marcelo Bigal sold 4,912 shares of the firm’s stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $23.67, for a total transaction of $116,267.04. Following the completion of the transaction, the director directly owned 11,393 shares in the company, valued at $269,672.31. This represents a 30.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pacira BioSciences Price Performance

Shares of PCRX opened at $25.19 on Tuesday. The company has a 50 day moving average of $23.57 and a two-hundred day moving average of $24.62. The company has a quick ratio of 1.91, a current ratio of 2.38 and a debt-to-equity ratio of 0.50. Pacira BioSciences, Inc. has a twelve month low of $11.16 and a twelve month high of $27.64. The company has a market cap of $1.13 billion, a price-to-earnings ratio of -9.06 and a beta of 0.48.

Pacira BioSciences (NASDAQ:PCRX) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.01. Pacira BioSciences had a negative net margin of 18.08% and a positive return on equity of 13.29%. The business had revenue of $181.10 million for the quarter, compared to analyst estimates of $183.11 million. During the same period in the previous year, the company earned $0.96 earnings per share. The business’s revenue for the quarter was up 1.7% on a year-over-year basis. As a group, analysts predict that Pacira BioSciences, Inc. will post 2.41 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Needham & Company LLC reduced their price target on shares of Pacira BioSciences from $32.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Wall Street Zen upgraded shares of Pacira BioSciences from a “hold” rating to a “buy” rating in a report on Friday, June 6th. Finally, Truist Financial upgraded shares of Pacira BioSciences from a “hold” rating to a “buy” rating and set a $30.00 price objective on the stock in a research note on Friday, July 25th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Pacira BioSciences has an average rating of “Moderate Buy” and an average target price of $25.75.

Hedge Funds Weigh In On Pacira BioSciences

Institutional investors and hedge funds have recently bought and sold shares of the company. State of Wyoming boosted its stake in Pacira BioSciences by 8.0% in the 4th quarter. State of Wyoming now owns 6,566 shares of the company’s stock worth $124,000 after purchasing an additional 487 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of Pacira BioSciences by 17.8% during the second quarter. PNC Financial Services Group Inc. now owns 3,511 shares of the company’s stock worth $84,000 after buying an additional 531 shares during the period. US Bancorp DE grew its holdings in shares of Pacira BioSciences by 31.0% during the first quarter. US Bancorp DE now owns 2,270 shares of the company’s stock valued at $56,000 after buying an additional 537 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Pacira BioSciences by 3.1% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,077 shares of the company’s stock valued at $491,000 after buying an additional 794 shares during the last quarter. Finally, Sterling Capital Management LLC grew its holdings in shares of Pacira BioSciences by 779.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock valued at $26,000 after buying an additional 1,208 shares during the last quarter. 99.73% of the stock is owned by hedge funds and other institutional investors.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.